Vanguard Group Inc Catalyst Pharmaceuticals, Inc. Transaction History
Vanguard Group Inc
- $5.37 Trillion
- Q1 2025
A detailed history of Vanguard Group Inc transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 8,495,580 shares of CPRX stock, worth $212 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,495,580
Previous 8,431,094
0.76%
Holding current value
$212 Million
Previous $176 Million
17.08%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding CPRX
# of Institutions
388Shares Held
99.3MCall Options Held
37KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$467 Million0.01% of portfolio
-
State Street Corp Boston, MA5.53MShares$138 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.42MShares$85.4 Million2.1% of portfolio
-
Goldman Sachs Group Inc New York, NY3.14MShares$78.3 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.96MShares$73.8 Million0.12% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.57B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...